Recent market reports forecast significant growth in the progressive pulmonary fibrosis market, set to reach $2.7 billion by 2035, and the global asthma and COPD drugs market, projected to hit US$ 82.2 billion by 2036. The Asia Pacific pharma 4.0 market is also expanding rapidly, driven by digital technologies like AI and IoT.
The EU Critical Medicines Act enters trilogue negotiations as drug shortages persist. The Parliament proposes broader powers for a new coordination group, binding stockpiling, and expanded MEAT procurement criteria. EMA recorded 136 critical shortages from 2022-2024.
A FAERS database analysis identified 13 FDA-approved systemic medications with disproportionately high uveitis reporting signals among 7,301 events from 2003 to 2024. The strongest signals were for cidofovir and rifabutin, and the findings were described as hypothesis-generating rather than causal.
